Competitive inhibition of heparinase by persulfonated glycosaminoglycans: a tool to detect heparin contamination
Research article published in Analytical chemistry (2011)
Abstract
Heparin and the low molecular weight heparins are extensively used as medicinal products to prevent and treat the formation of venous and arterial thrombi. In early 2008, administration of some heparin lots was associated with the advent of severe adverse effects, indicative of an anaphylactoid-like response. Application of orthogonal analytical tools enabled detection and identification of the contaminant as oversulfated chondroitin sulfate (OSCS) was reported in our earlier report. Herein, we investigate whether enzymatic depolymerization using the bacterially derived heparinases, given the structural understanding of their substrate specificity, can be used to identify the presence of OSCS in heparin. We also extend this analysis to examine the effect of other persulfonated glycosaminoglycans (GAGs) on the action of the heparinases. We find that all persulfonated GAGs examined were effective inhibitors of heparinase I, with IC(50) values ranging from approximately 0.5-2 μg/mL. Finally, using this biochemical understanding, we develop a rapid, simple assay to assess the purity of heparin using heparinase digestion followed by size-exclusion HPLC analysis to identify and quantify digestion products. In the context of the assay, we demonstrate that less than 0.1% (w/w) of OSCS (and other persulfonated polysaccharides) can routinely be detected in heparin.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Heparin and the low molecular weight heparins are extensively used as medicinal products to prevent and treat the formation of venous and arterial thrombi.
Why This Matters for Hirudotherapy
This biochemical study found that persulfonated glycosaminoglycans, including the oversulfated chondroitin sulfate (OSCS) implicated in the 2008 contaminated-heparin adverse events, competitively inhibit bacterial heparinase I (IC50 roughly 0.5-2 micrograms/mL), and on that basis the authors developed a heparinase-digestion plus size-exclusion HPLC assay able to detect under 0.1% OSCS contamination in heparin. It is tangential to hirudotherapy itself but relevant to the wider anticoagulant and enzyme-pharmacology context the ASH evidence library tracks, showing how an enzyme's substrate specificity can be turned into a quality-control tool for a widely used blood thinner. As an in-vitro analytical-methods study, it validates a contamination assay and the inhibition behavior of these compounds, and does not address clinical use of heparin, leeches, or any treatment outcome.
Citation
Competitive inhibition of heparinase by persulfonated glycosaminoglycans: a tool to detect heparin contamination
Aich U et al. · Analytical chemistry, 2011
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026